title: Development of erythroleukaemia after myelodysplastic syndrome in a patient with Wegener's granulomatosis.
authors.forename: T
authors.initials: T
authors.lastname: Takaoka
authors.forename: Y
authors.initials: Y
authors.lastname: Matsukawa
authors.forename: Y
authors.initials: Y
authors.lastname: Tomita
authors.forename: N
authors.initials: N
authors.lastname: Kitamura
authors.forename: T
authors.initials: T
authors.lastname: Yamazaki
authors.forename: J
authors.initials: J
authors.lastname: Takeuchi
authors.forename: S
authors.initials: S
authors.lastname: Nishinarita
authors.forename: U
authors.initials: U
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Horie
mesh_terms: D003520:Cyclophosphamide / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000209:etiology*
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide